Supernus Pharmaceuticals Stock News

ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.43 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen

Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged loc

Supernus Pharmaceuticals has experienced revenue growth every year since its IPO in 2021, reaching $667m in 2022. The company has expanded its product portfolio through acquisitions, including the pur

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est

Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.03 per share a year ago.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Jack Khattar – Chief Executive Offi

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen

ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce